According to a new report LAMEA Biochips Market, published by KBV research, the LAMEA Biochips Market would witness market growth of 12.3% CAGR during the forecast period (2019-2025).
The Brazil market dominated the LAMEA Disease Diagnostics Market by Country in 2018, growing at a CAGR of 10.9 % during the forecast period. The Argentina market is expected to witness a CAGR of 13% during (2019 - 2025). Additionally, The UAE market is expected to witness a CAGR of 11.4% during (2019 - 2025).
The Lab-on-Chip market dominated the UAE Biochips Market by Product in 2018, growing at a CAGR of 11.5 % during the forecast period. The DNA Chip market is expected to witness a CAGR of 11.4% during (2019 - 2025).
The Biotechnology and Pharmaceutical Sector market dominated the South Africa Biochips Market by End User in 2018, growing at a CAGR of 12.5 % during the forecast period. The Hospitals and Diagnostics Centers market is expected to witness a CAGR of 12.4% during (2019 - 2025). The Academic and Research Institutes market is expected to witness a CAGR of 14.3% during (2019 - 2025).
Full Report:https://www.kbvresearch.com/lamea-biochips-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the mentioned countries. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Fluidigm Corporation, Horiba Ltd., PerkinElmer, Inc., OriGene Technologies, Inc., Dynamic Biosensors GmbH, Illumina, Inc., Qiagen N.V., Bio-Rad Laboratories, Inc., Randox Laboratories Limited, Thermo Fisher Scientific, Inc.
ByProduct
By Application
By End User
By Country
Companies Profiled
Unique Offerings from KBV Research
Unique Offerings 
